This ExpertREACT article was originally published on 29 May 2009. Market data and partnership details described reflect the state of knowledge at that date.
Japan: a $600m market with room to grow
Western vaccine companies were increasingly vocal about Japan as a strategic priority vaccine market. Both GSK and Novartis Vaccines estimated the Japanese vaccine market at approximately $600m with potential for further growth. Japan's annual birth cohort of approximately 1.2 million was expected to remain flat, but the country's immunisation schedule - less developed than US and EU frameworks - offered significant gaps that new vaccines could fill. Unlike emerging markets such as China, India and Brazil driven by growing wealth and birth rates, Japan's opportunity was defined by its under-vaccination relative to the developed world standard and its willingness to pay international pricing for approved vaccines.
The most recent move was Novartis Vaccines' marketing and distribution agreement with Takeda Pharmaceuticals for Vaxem-Hib - a vaccine preventing infections caused by Haemophilus influenzae type b - building on Novartis' earlier Intercell deal for Ixiaro (Japanese encephalitis). Sanofi Pasteur had preceded Novartis by signing a deal with Daiichi-Sankyo in November 2008 for ActHIB (Hib vaccine), claiming first-mover status as the first international company to enter the Japanese paediatric vaccine market. GSK, which had no direct Japanese vaccine presence at the time of its public declaration, was now actively building its market entry strategy. Astellas Pharma had independently in-licensed Vical's therapeutic CMV vaccine (Transvax), demonstrating that therapeutic vaccine approaches also attracted Japanese company interest.
Local partnership: a non-negotiable requirement
VacZine Analytics noted that Japan's regulatory environment, distribution infrastructure and physician relationship dynamics made local partnership a non-negotiable requirement for market entry by Western vaccine companies. Unlike emerging markets where international companies could sometimes operate directly through subsidiaries, Japan's market gatekeeping structures meant that access to the domestic market without a well-established local partner was practically unfeasible. The pattern of partnership - Novartis/Takeda, Sanofi/Daiichi-Sankyo - was expected to become the template for all Western vaccine entrants seeking a meaningful share of Japan's growing market.